☆ 4.7 Meeting Abstract

MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB-IVM1c melanoma (MEL)

ANNALS OF ONCOLOGY (2021)

Get Full Text
Add to Collection

Journal

ANNALS OF ONCOLOGY
Volume 32, Issue -, Pages S868-S869

Publisher

ELSEVIER
DOI: 10.1016/j.annonc.2021.08.1422

Keywords

-

Categories

Oncology

Funding

  1. Amgen Inc.
  2. Merck Co.

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.